Business
dsm-firmenich Q1 2025 trading update
Press ReleaseKaiseraugst (Switzerland), Maastricht (Netherlands), April 30, 2025 dsm-firmenich Q1 2025 trading update Management Report Q1 2025 highlights Good start to the year with strong organic sales and earnings growthProgressing well on 2025 strategic planSale of Feed Enzymes business for €1.5 billion announcedAnimal Nutrition & Health exit process advancing as planned€1 billion share buyback program commenced in AprilFY 2025 outlook unchanged: Adjusted EBITDA at least €2.4 billion Key fig
About this update from Dsm-firmenich Ag
[{"type":"image","alt":"dsm-firmenich","displaySize":"","headline":null,"caption":"dsm-firmenich","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/9b415d4a2865afc6fd1cf942611724d8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mMYFeKUNdZU9mGc.nThqBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/9b415d4a2865afc6fd1cf942611724d8","width":300,"height":58}},"lazy":false},{"type":"text","content":"Press ReleaseKaiseraugst (Switzerland), Maastricht (Netherlands), April 30, 2025","length":81,"tagName":"p"},{"type":"text","content":"dsm-firmenich Q1 2025 trading update","length":36,"tagName":"p"},{"type":"text","content":"Management Report","length":17,"tagName":"p"},{"type":"text","content":"Q1 2025 highlights ","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Good start to the year with strong organic sales and earnings growth","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Progressing well on 2025 strategic plan","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"Sale of Feed Enzymes business for €1.5 billion announced","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Animal Nutrition & Health exit process advancing as planned","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"€1 billion share buyback program commenced in April","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"FY 2025 outlook unchanged: Adjusted EBITDA at least €2.4 billion","length":64,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":341,"olType":false},{"type":"text","content":"Key figures ","length":11,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:25%;width:25%;min-width:25%;border-bottom:solid black 1pt;vertical-align:bottom;","val":[{"type":"text","content":"in € millions","length":13,"tagName":"p","attribs":{}}]},{"style":"max-width:25%;width:25%;min-width:25%;border-bottom:solid black 1pt;text-align:right;vertical-align:middle;vertical-align:bottom;","val":[{"type":"text","content":"Q1 2025","length":7,"tagName":"p","attribs":{}}]},{"style":"max-width:25%;width:25%;min-width:25%;border-bottom:solid black 1pt;text-align:right;vertical-align:middle;vertical-align:bottom;","val":[{"type"...